Alain Stintzi

Alain Stintzi

Auto-generated profile, based on publicly available information

Alain Stintzi

School of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Clinical Nutrition
Verified
Journal Article
Open access
KHKendra Hodgkinson
Kendra Hodgkinson
FAFaiha El Abbar
Faiha El Abbar
PDPeter Dobranowski
Peter Dobranowski
JMJuliana Manoogian
Juliana Manoogian
JBJames Butcher
James Butcher
ASAlain Stintzi
Alain Stintzi
Butyrate is a key energy source for colonocytes and is produced by the gut microbiota through fermentation of dietary fiber. Butyrate is a histone deacetylase inhibitor and also signals through three G-protein coupled receptors. It is clear that butyrate has an important role in gastrointestinal health and that butyrate levels can impact both host and microbial functions that are intimately coupled with each other. Maintaining optimal butyrate levels improves gastrointestinal health in animal models by supporting colonocyte function, decreasing inflammation, maintaining the gut barrier, and promoting a healthy microbiome. Butyrate has also shown protective actions in the context of intestinal diseases such as inflammatory bowel disease, graft-versus-host disease of the gastrointestinal tract, and colon cancer, whereas lower levels of butyrate and/or the microbes which are responsible for producing this metabolite are associated with disease and poorer health outcomes. However, clinical efforts to increase butyrate levels in humans and reverse these negative outcomes have generated mixed results. This article discusses our current understanding of the molecular mechanisms of butyrate action with a focus on the gastrointestinal system, the links between host and microbial factors, and the efforts that are currently underway to apply the knowledge gained from the bench to bedside.

23 November 2016 in Nature Communications
Verified
Journal Article
Open access
Walid MottaweaWalid Mottawea
Walid Mottawea
CCCheng-Kang Chiang
Cheng-Kang Chiang
MMMarcus Mühlbauer
Marcus Mühlbauer
ASAmanda E. Starr
Amanda E. Starr
JBJames Butcher
James Butcher
ASAlain Stintzi
Alain Stintzi
Intestinal microbial dysbiosis is associated with Crohn’s disease (CD). However, the mechanisms leading to the chronic mucosal inflammation that characterizes this disease remain unclear. In this report, we use systems-level approaches to study the interactions between the gut microbiota and host in new-onset paediatric patients to evaluate causality and mechanisms of disease. We report an altered host proteome in CD patients indicative of impaired mitochondrial functions. In particular, mitochondrial proteins implicated in H2S detoxification are downregulated, while the relative abundance of H2S microbial producers is increased. Network correlation analysis reveals that Atopobium parvulum controls the central hub of H2S producers. A. parvulum induces pancolitis in colitis-susceptible interleukin-10-deficient mice and this phenotype requires the presence of the intestinal microbiota. Administrating the H2S scavenger bismuth mitigates A. parvulum-induced colitis in vivo. This study reveals that host–microbiota interactions are disturbed in CD and thus provides mechanistic insights into CD pathogenesis.

6 December 2019 in Microbiome
Verified
Journal Article
Open access
PDF file
XZXu Zhang
Xu Zhang
Leyuan LiLeyuan Li
Leyuan Li
JBJames Butcher
James Butcher
ASAlain Stintzi
Alain Stintzi
DFDaniel Figeys
Daniel Figeys
The gut microbiome has emerged as an important factor affecting human health and disease. The recent development of –omics approaches, including phylogenetic marker-based microbiome profiling, shotgun metagenomics, metatranscriptomics, metaproteomics, and metabolomics, has enabled efficient characterization of microbial communities. These techniques can provide strain-level taxonomic resolution of the taxa present in microbiomes, assess the potential functions encoded by the microbial community and quantify the metabolic activities occurring within a complex microbiome. The application of these meta-omics approaches to clinical samples has identified microbial species, metabolic pathways, and metabolites that are associated with the development and treatment of human diseases. These findings have further facilitated microbiome-targeted drug discovery and efforts to improve human health management. Recent in vitro and in vivo investigations have uncovered the presence of extensive drug-microbiome interactions. These interactions have also been shown to be important contributors to the disparate patient responses to treatment that are often observed during disease therapy. Therefore, developing techniques or frameworks that enable rapid screening, detailed evaluation, and accurate prediction of drug/host-microbiome interactions is critically important in the modern era of microbiome research and precision medicine. Here we review the current status of meta-omics techniques, including integrative multi-omics approaches, for characterizing the microbiome’s functionality in the context of health and disease. We also summarize and discuss new frameworks for applying meta-omics approaches and microbiome assays to study drug-microbiome interactions. Lastly, we discuss and exemplify strategies for implementing microbiome-based precision medicines using these meta-omics approaches and high throughput microbiome assays.

11 March 2020 in Microbiome
Verified
Journal Article
Open access
PDF file
Leyuan LiLeyuan Li
Leyuan Li
ZNZhibin Ning
Zhibin Ning
XZXu Zhang
Xu Zhang
JMJanice Mayne
Janice Mayne
KCKai Cheng
Kai Cheng
DFDaniel Figeys
Daniel Figeys
Background: Human-targeted drugs may exert off-target effects or can be repurposed to modulate the gut microbiota. However, our understanding of such effects is limited due to a lack of rapid and scalable assay to comprehensively assess microbiome responses to drugs. Drugs and other compounds can drastically change the overall abundance, taxonomic composition, and functions of a gut microbiome.Results: Here, we developed an approach to screen compounds against individual microbiomes in vitro, using metaproteomics to both measure absolute bacterial abundances and to functionally profile the microbiome. Our approach was evaluated by testing 43 compounds (including 4 antibiotics) against 5 individual microbiomes. The method generated technically highly reproducible readouts, including changes of overall microbiome abundance, microbiome composition, and functional pathways. Results show that besides the antibiotics, the compounds berberine and ibuprofen inhibited the accumulation of biomass during in vitro growth of the microbiota. By comparing genus and species level-biomass contributions, selective antibacterial-like activities were found with 35 of the 39 non-antibiotic compounds. Seven of the compounds led to a global alteration of the metaproteome, with apparent compound-specific patterns of functional responses. The taxonomic distributions of altered proteins varied among drugs, i.e., different drugs affect functions of different members of the microbiome. We also showed that bacterial function can shift in response to drugs without a change in the abundance of the bacteria.Conclusions: Current drug-microbiome interaction studies largely focus on relative microbiome composition and microbial drug metabolism. In contrast, our workflow enables multiple insights into microbiome absolute abundance and functional responses to drugs. The workflow is robust, reproducible, and quantitative and is scalable for personalized high-throughput drug screening applications.

20 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
XZXu Zhang
Xu Zhang
SDShelley A. Deeke
Shelley A. Deeke
ZNZhibin Ning
Zhibin Ning
ASAmanda E. Starr
Amanda E. Starr
JBJames Butcher
James Butcher
DFDaniel Figeys
Daniel Figeys
Alterations in gut microbiota have been implicated in the pathogenesis of inflammatory bowel disease (IBD), however factors that mediate the host–microbiota interactions remain largely unknown. Here we collected mucosal-luminal interface samples from a pediatric IBD inception cohort and characterized both the human and microbiota proteins using metaproteomics. We show that microbial proteins related to oxidative stress responses are upregulated in IBD cases compared to controls. In particular, we demonstrate that the expression of human proteins related to oxidative antimicrobial activities is increased in IBD cases and correlates with the alteration of microbial functions. Additionally, we reveal that many of these human proteins are present and show altered abundance in isolated free extracellular vesicles (EVs). Therefore, our study suggests that the alteration of intestinal EV proteomes is associated with the aberrant host–microbiota interactions in IBD.

11 April 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MSMartin Stahl
Martin Stahl
LFLorna M. Friis
Lorna M. Friis
HNHarald Nothaft
Harald Nothaft
XLXin Liu
Xin Liu
JLJianjun Li
Jianjun Li
ASAlain Stintzi
Alain Stintzi
Campylobacter jejuni is a prevalent gastrointestinal pathogen in humans and a common commensal of poultry. When colonizing its hosts, C. jejuni comes into contact with intestinal carbohydrates, including l -fucose, released from mucin glycoproteins. Several strains of C. jejuni possess a genomic island ( cj0480c–cj0490 ) that is up-regulated in the presence of both l -fucose and mucin and allows for the utilization of l -fucose as a substrate for growth. Strains possessing this genomic island show increased growth in the presence of l -fucose and mutation of cj0481 , cj0486 , and cj0487 results in the loss of the ability to grow on this substrate. Furthermore, mutants in the putative fucose permease ( cj0486 ) are deficient in fucose uptake and demonstrate a competitive disadvantage when colonizing the piglet model of human disease, which is not paralleled in the colonization of poultry. This identifies a previously unrecorded metabolic pathway in select strains of C. jejuni associated with a virulent lifestyle.